Mary V. Relling
Department of Pharmaceutical Sciences
St. Jude Children's Research Hospital
Memphis
Tennessee
USA
Name/email consistency: high
- Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Relling, M.V., Gardner, E.E., Sandborn, W.J., Schmiegelow, K., Pui, C.H., Yee, S.W., Stein, C.M., Carrillo, M., Evans, W.E., Klein, T.E. Clin. Pharmacol. Ther. (2011)
- Should pharmacogenomic studies be required for new drug approval?. Relling, M.V., Hoffman, J.M. Clin. Pharmacol. Ther. (2007)
- Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. Relling, M.V., Yang, W., Das, S., Cook, E.H., Rosner, G.L., Neel, M., Howard, S., Ribeiro, R., Sandlund, J.T., Pui, C.H., Kaste, S.C. J. Clin. Oncol. (2004)
- Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Relling, M.V., Boyett, J.M., Blanco, J.G., Raimondi, S., Behm, F.G., Sandlund, J.T., Rivera, G.K., Kun, L.E., Evans, W.E., Pui, C.H. Blood (2003)
- Pharmacogenetics and cancer therapy. Relling, M.V., Dervieux, T. Nat. Rev. Cancer (2001)
- Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Relling, M.V., Pui, C.H., Sandlund, J.T., Rivera, G.K., Hancock, M.L., Boyett, J.M., Schuetz, E.G., Evans, W.E. Lancet (2000)
- Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. Relling, M.V., Hancock, M.L., Rivera, G.K., Sandlund, J.T., Ribeiro, R.C., Krynetski, E.Y., Pui, C.H., Evans, W.E. J. Natl. Cancer Inst. (1999)